No Data
No Data
No Data
No Data
No Data
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals' V Oquezna
TipRanksApr 26 20:25
SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m...
PR NewswireApr 22 15:30
13D Filings -- Barron's
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Barron'sApr 20 09:30
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Barron'sApr 20 03:03
12 Most Shorted Stocks in 2024
Yahoo FinanceApr 19 23:02
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V Oquezna
TipRanksApr 19 21:25
No Data
No Data